Table 2 Treatment-emergent adverse events (AEs)

From: Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Adverse event (AE) Placebo
No. of events (no. of events/patient)
NR
No. of events (no. of events/patient)
Headache 4 (1) 0 (0)
Nausea 0 (0) 1 (1)
Skin rash 1 (1) 1 (1)
Flushing/Hot flashes 2 (1) 1 (1)
Fainting 1 (1) 0 (0)
Drowsiness 1 (1) 0 (0)
Leg cramps 0 (0) 1 (1)
Increased bruising 0 (0) 1 (1)
  1. Data represent number (n) of times AE was reported. Number of subjects reporting AEs (n = 7); Number of subjects reporting ≥2 AE (n = 5)
  2. Obtained from self-report during bi-weekly check-in visits over each phase. Based on N = 30 randomized subjects